TABLE 2.
Effects of candidate SPs on infection with clinical isolatesa
| Clinical isolate | IC50 (μg/ml)/IC90 (μg/ml)
|
|||
|---|---|---|---|---|
| PRO 2000 | PSS | CS | PMHS | |
| WTWIA | 0.1/1.0 | 0.07/0.7 | 0.6/8.0 | 0.4/1.0 |
| MMA | 0.1/1.0 | 0.07/0.7 | 0.6/8.0 | 0.4/1.0 |
| DT-1 | 0.1/1.0 | 0.07/0.7 | 0.6/8.0 | 0.4/1.0 |
| DT-2 | 0.1/1.0 | 0.07/0.7 | 0.6/8.0 | 0.4/1.0 |
a
CaSki cells were infected with clinical isolates (MMA, WTWIA, DT-1) or an acyclovir-resistant clinical isolate (DT-2) of HSV-2 in the absence or presence of different concentrations of each candidate drug. The IC50s and IC90s were determined from dose-response curves generated from three independent experiments performed in duplicate.